Hosted on MSN29m
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...